Clinical Trial Update: Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of carboplatin, gemcitabine, and bevacizumab in locally advanced or metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Locally Advanced Non-Small Cell Lung Cancer, NSCLC | Phase 2 | Status: COMPLETED